

# The TOP 200

BY SUE CAVALLUCCI

## What's making waves in prescription sales

**A**FTER HIGHLY PUBLICIZED FALLS FOR SOME OF CANADA'S "most prescribed" in each of the past three years, 2006 will be remembered for a period of stability prevailing over Canada's Top 200 prescription medications. Only 15 new entries appear on the list this year compared to 23 in 2005, and no changes were seen in the top 10 prescribed medications or the top prescribed classes.

Total prescriptions dispensed in Canadian retail pharmacies increased by 5.7% in 2006, up from 3.6% in 2005. A rebound in the classes affected by recent safety warnings—COX-2 inhibitors, hormone replacement therapy (HRT), antidepressants and major tranquilizers—has contributed to this year's increased growth in prescriptions dispensed.

Canadians spent \$19 billion on prescription medications in their retail pharmacies (includes dispensing fees) and had 414 million prescriptions filled from October 2005 to September 2006. This represents an average of 13 prescriptions annually for every Canadian, at an average retail price of \$46.07 per prescription.

Canadians aged  $\geq 80$ , 60–79 and 40–59 filled an average of 74, 35 and 15 prescriptions per capita, respectively, in 2005.

The Top 200 prescription products, which accounted for almost two-thirds of all prescriptions dispensed in the 12 months ending September 2006, included some new entries this year: bisphosphonates Apo-Alendronate (#99) and Novo-

Alendronate (#138), analgesic Ratio-Lenoltec #3 (#134), oral contraceptive Yasmin (#171), beta-blocker Apo-Bisoprolol (#150), antidepressant Novo-Bupropion SR (#151), benzodiazepine Apo-Clonazepam (#152), erectile dysfunction medication Cialis (#189), fluoroquinolone Avelox (#188) and vaccine (against hepatitis A and B) Twinrix (#182). Of the 15 new medications that made it to the Top 200, nine were generic and six were brand-name.

For the third straight year, cholesterol reducer Lipitor was Canada's most dispensed drug, with 12.3 million prescriptions. Among the top 10 prescribed drugs, anti-inflammatory Asaphen (acetylsalicylic acid [ASA]) grew the fastest in 2006, up 29% from last year. Its rise is likely due to the recent increased emphasis on the use of daily ASA for cardiovascular prophylaxis in a wider range of patients.

The second fastest-growing Top 10 product is proton pump inhibitor Pantoloc, leading some to question whether its rise is associated with increased use of older NSAIDs, a consequence of the safety warnings issued for COX-2 inhibitors in 2004. This does not seem to be the case. Pantoloc's growth has actually slowed since 2004, as is true for all proton pump inhibitors.

Cholesterol reducers continue to be the fastest growing among Canada's most dispensed classes, followed closely by antispasmodic and antisecretory agents. In addition, for the first time

### About IMS Health

The information for this article was obtained from IMS Health Canada's CompuScript, Xponent and Canadian Drug Store and Hospital Purchases databases. Established in 1954, IMS is the world's leading private-sector provider of market intelligence and consulting solutions to the pharmaceutical and medical communities.

Sue Cavallucci is manager of Media and Public Affairs at IMS Health Canada in Montreal, Que.  
She regularly provides prescription and diagnostic information to Canadian media.

since the safety warnings were issued for HRT in 2002, Canada's hormones class posted a growth. This year, the anti-infective class was the only Top 10 class to post a decrease, perhaps reflecting that educational campaigns aimed at curbing antibiotic use are having an effect.

Generic manufacturers account for half of the Top 200 products: Apotex manufactured 44 products, followed by Novopharm with 18, Pharmascience with 10, and Ratiopharm and Genpharm each with nine.

New to the Top 200 this year are breakdowns of prescriptions dispensed by age and gender. The top dispensed drug classes for women of all ages were antidepressants, tranquilizers (i.e., phenothiazines and benzodiazepines) and cholesterol reducers;

for men, they were cholesterol reducers, antidepressants, and angiotensin-converting enzyme (ACE) inhibitors (single entity and combinations). Looking at the most commonly prescribed classes for women and men aged 0-39, it is important to note that the antidepressant class includes medications for attention deficit hyperactivity disorder. This helps explain why the class ranks among the top-five prescribed classes for this age group.

## What are the top 100 drugs in new and refill scripts?

Find out at [www.pharmacygateway.ca](http://www.pharmacygateway.ca). Go to Our publications, *Pharmacy Practice*, December 2006, Top 200.

### TOP 10 therapeutic classes

Rank '06*	Rank '05*	Therapeutic class	% change**
1	1	CARDIOVASCULARS	7.2
2	2	PSYCHOTHERAPEUTICS	7.1
3	3	HORMONES	2
4	4	ANTI-INFECTIVES, SYSTEMIC	-1.6
5	5	ANTIHYPERLIPIDEMIC AGENTS	10.5
6	6	ANTISPASMODIC/ANTISECRETORY	9.3
7	7	ANALGESICS	3.8
8	9	DIABETES THERAPY	9.7
9	8	DIURETICS	5.1
10	10	BRONCHIAL THERAPY	0.3

\*Ranking based on estimated number of prescriptions dispensed in Canadian retail pharmacies in the 12 months ending September 2006 and September 2005, respectively; \*\*Percentage change in growth from 12 months ending September 2005 to 12 months ending September 2006

Copyright IMS HEALTH

Source: Canadian CompuScript Audit

### 10 FASTEST-GROWING therapeutic classes

Rank '06*	Therapeutic class	Estimated purchases (\$000)	% change**
1	GOUT-SPECIFIC PREPARATIONS (allopurinol, colchicine, probenecid)	11,745	119.1
2	ANTINEOPLASTICS (biological response modifiers, monoclonal antibodies, enzyme receptor inhibitors, platinum derivatives)	362,388	62.9
3	ANESTHESIC, GENERAL	24,989	40.0
4	NARROW SPECTRUM ANTIVIRAL (antiretrovirals)	260,016	18.8
5	DIABETES THERAPY, INSULIN	181,845	17.5
6	VACCINES RESPIRATORY (Pevnar, influenza [Influvac, Vaxigrip, Fluviral S/F])	68,732	17.2
7	LAXATIVE, SALINE	10,872	17.0
8	ANTISPASMODIC, GI (e.g., domperidone, metoclopramide, NOT PPIs or H2-receptor antagonists)	80,684	15.9
9	DIABETES THERAPY, ORAL	374,071	15.7
10	ANGIOTENSIN II RECEPTOR BLOCKER AND COMBINATIONS (alone or with diuretics)	488,620	15.5

\*Ranking based on growth of estimated purchases made by Canadian drugstores and hospitals in the 12 months ending September 2006. Includes only those classes with more than \$10 million in annual sales; \*\*Percentage change in growth from 12 months ending September 2005 to 12 months ending September 2006

Copyright IMS HEALTH

Source: Canadian Drug Store and Hospital Purchases Audit

### Top therapeutic classes by AGE AND GENDER\*

WOMEN 0 - 39		MEN 0 - 39	
	%**		%**
ORAL CONTRACEPTIVES	21.0	ANTI-INFECTIVES, ANTIBIOTICS	12.3
ANTI-INFECTIVES, ANTIBIOTICS	9.1	ANTIDEPRESSANTS	11.6
ANTIDEPRESSANTS	8.8	TRANQUILLIZERS	5.8
TRANQUILLIZERS	3.2	ANALGESICS NARCOTICS	4.1
ACNE THERAPY	2.5	SEIZURE DISORDERS	3.6
PLAIN CORTICOSTEROIDS	1.3	ASTHMA THERAPY	2.8
WOMEN 40 - 59		MEN 40 - 59	
	%**		%**
ANTIDEPRESSANTS	10.3	CHOLESTEROL REDUCERS	9.1
TRANQUILLIZERS	6.4	ANTIDEPRESSANTS	7.1
THYROID HORMONE	4.4	TRANQUILLIZERS	6.6
WOMEN 60 +		MEN 60 +	
	%**		%**
DIURETICS, NON-INJECTABLE	5.9	CHOLESTEROL REDUCERS	9.1
TRANQUILLIZERS	5.3	ACE INHIBITORS AND COMBINATIONS	6.5
CHOLESTEROL REDUCERS	4.6	BETA-BLOCKER AND COMBINATIONS	5.4
CALCIUM-BLOCKING AGENTS	3.6	ANALGESICS	5.2

\*Based on estimated prescriptions dispensed in Canadian retail pharmacies in the following provinces: Saskatchewan, Alberta, Ontario, Quebec, New Brunswick and Nova Scotia. Period covers 12 months ending September 2006; \*\*Percentage of prescriptions dispensed for the age group

Copyright IMS HEALTH

Source: Xponent

### 10 SLOWEST-GROWING therapeutic classes

Rank '06*	Therapeutic class	Estimated purchases (\$000)	% change**
1	ANTINEOPLASTICS: Antimitotic agents/plant derivatives (taxoids, DNA topoisomerase inhibitors, vinca alkaloids, podophylotoxin derivatives)	109,093	-15.6
2	VITAMINS (all vitamins except, vitamin C, multivitamins and B-complex)	35,628	-10.6
3	ANTACIDS, plain or with antifatulents	15,027	-9.4
4	COUGH ONLY PREPS (with and without expectorants)	30,778	-9.4
5	COLD PREPS ORAL (with and without analgesics)	31,217	-9.3
6	ANTINEOPLASTICS: Cytostatic antibiotics (anthracyclines, mitomycin, bleomycin, dactinomycin)	31,949	-9.3
7	VACCINES, BIOLOGICAL (all vaccines except influenza vaccines, pneumococcal conjugate vaccine)	68,535	-9.3
8	ACNE THERAPY	78,612	-7.6
9	QUINOLONES	131,957	-6.5
10	INFANT FORMULA, ROUTINE	30,059	-5.9

\*Ranking based on growth of estimated purchases made by Canadian drugstores and hospitals in the 12 months ending September 2006. Includes only those classes with more than \$10 million in annual sales; \*\*Percentage change in growth from 12 months ending September 2005 to 12 months ending September 2006

Copyright IMS HEALTH

Source: Canadian Drug Store and Hospital Purchases Audit

Rank '06	Rank '05	Product	Launch Date (mmyy)	Manufacturer	% change**	Rank '06	Rank '05	Product	Launch Date (mmyy)	Manufacturer	% change**
1	1	LIPITOR	Mar-97	Pfizer	13.1	51	48	COUMADIN	May-56	Bristol-Myers Squibb	-0.5
2	2	SYNTHROID	Jan-57	Abbott	7.2	52	61	DIOVAN	Nov-97	Novartis	18.7
3	3	ALTACE	Jan-94	Sanofi-Aventis	9.8	53	57	ATACAND	Dec-98	AstraZeneca	13.7
4	4	NOVASC	Sep-92	Pfizer	14.4	54	60	RIVASA	Mar-00	Riva	11
5	5	EFFEXOR XR	Mar-98	Wyeth	14.7	55	58	RATIO-OXYCOCET	Apr-84	Ratiopharm	4.4
6	7	ASAPHEN	May-95	Pharmascience	28.9	56	59	ARTHROTEC	Apr-93	Pfizer	4.3
7	8	PANTOLOC	Mar-97	Solvay Pharma	15.4	57	19	FOSAMAX	Jan-96	Merck Frosst	-49.8
8	6	TYLENOL W/COD #3	Jan-71	Janssen-Ortho	-10.1	58	51	APO-SIMVASTATIN	Jan-03	Apotex	-5.1
9	9	RATIO-SALBUTAMOL HFA	Feb-02	Ratiopharm	3.1	59	55	NITRO-DUR	Feb-91	Schering	-3.5
10	10	APO-FUROSEMIDE	Jun-76	Apotex	5.4	60	87	APO-CITALOPRAM	Jan-04	Apotex	33.9
11	12	APO-HYDRO	Oct-74	Apotex	4.1	61	56	FLONASE	Sep-93	GlaxoSmithKline	-2
12	11	NOVASEN	Jan-76	Novopharm	-13.5	62	65	COZAAR	Oct-95	Merck Frosst	3.4
13	26	CRESTOR	Feb-03	AstraZeneca	28.1	63	92	COVERSYL	Nov-94	Servier Lab	32.5
14	28	PARIET	Jul-02	Janssen-Ortho	38.2	64	68	APO-RANITIDINE	Mar-87	Apotex	5.3
15	13	NOVO-HYDRAZIDE	Jan-70	Novopharm	8.6	65	64	PMS-CLONAZEPAM-R	Mar-96	Pharmascience	-0.3
16	27	APO-AMOXI	Aug-84	Apotex	28.7	66	63	XALATAN	Jul-97	Pfizer	-1.1
17	15	ADALAT XL	Apr-92	Bayer	3.9	67	116	CALCITE 500+D 400	Oct-02	Riva	53.5
18	16	ALESSE	Jan-98	Wyeth	5.1	68	75	AVANDIA	Mar-00	GlaxoSmithKline	15.5
19	31	SEROQUEL	Jan-98	AstraZeneca	29.4	69	77	SANDOZ-BISOPROLOL	Aug-03	Sandoz	18.8
20	17	APO-LORAZEPAM	Nov-85	Apotex	2.4	70	98	APO-METOPROLOL	Oct-84	Apotex	31.5
21	21	ATIVAN	Apr-77	Wyeth	2.1	71	82	NOVO-GLYBURIDE	Nov-91	Novopharm	17.2
22	18	FLOVENT HFA	Feb-02	GlaxoSmithKline	-1.6	72	71	ADVAIR	Oct-99	GlaxoSmithKline	2.6
23	24	RISPERDAL	May-93	Janssen-Ortho	3.8	73	97	CARBOCAL D 400	Jul-02	Europharm	23.6
24	23	APO-AMITRIPTYLINE	Jun-75	Apotex	1.1	74	88	OXYCONTIN	Aug-96	Purdue Pharma	18.7
25	30	PLAVIX	Oct-98	Bristol-Myers Squibb	13.7	75	122	APO-METFORMIN	Sep-95	Apotex	52.3
26	20	PREMARIN	Feb-42	Wyeth	-4.6	76	69	APO-METOPROLOL-L	May-87	Apotex	-5.3
27	35	NEXIUM	Aug-01	AstraZeneca	15.5	77	70	APO-LISINAPRIL	Dec-96	Apotex	-3.4
28	22	CELEBREX	Apr-99	Pfizer	-9.6	78	83	APO-CEPHALEX	Aug-88	Apotex	10.6
29	32	ELTROXIN	Jan-51	GlaxoSmithKline	4.2	79	121	APO-PAROXETINE	Oct-03	Apotex	38.8
30	38	ACTONEL	Nov-99	P&G Pharma	22.7	80	90	NOVO-SEMIDE	Aug-76	Novopharm	12.5
31	34	APO-OXAZEPAM	Sep-79	Apotex	0.4	81	123	ONE TOUCH ULTRA	Mar-01	LifeScan	42
32	14	LOSEC	Jun-89	AstraZeneca	-27.1	82	101	AVALIDE	Apr-00	Bristol-Myers Squibb	15.5
33	29	TRI-CYCLEN	Jul-93	Janssen-Ortho	-9.1	83	45	GEN-CITALOPRAM	Feb-04	Genpharm	-33.8
34	37	PREVACID	Jun-95	Abbott	8	84	96	NOVO-GESIC	Nov-82	Novopharm	11.8
35	33	VASOTEC	Aug-87	Merck Frosst	-6.9	85	86	APO-GLYBURIDE	Nov-91	Apotex	7.3
36	47	GEN-METFORMIN	Apr-95	Genpharm	26.6	86	112	DIOVAN HCT	May-00	Novartis	22.7
37	36	ZYPREXA	Nov-96	Lilly	3.4	87	79	DILANTIN SODIUM	Jan-52	Pfizer	2.4
38	67	APO-OMEPRAZOLE	Jan-04	Apotex	54	88	66	BIAXIN BID	Jul-92	Abbott	-14.7
39	39	LANOXIN	Jan-36	Virco Pharma	-0.8	89	107	APO-FOLIC	Jun-78	Apotex	18.5
40	40	PMS-METFORMIN	Feb-97	Pharmascience	3.2	90	89	NOVO-LORAZEM	Apr-85	Novopharm	7.3
41	43	NASONEX	Aug-98	Schering	7.3	91	106	ASPIRIN	Jan-51	Bayer CCD	15.4
42	46	AVAPRO	Jun-98	Bristol-Myers Squibb	13.2	92	102	GEN-SIMVASTATIN	Feb-03	Genpharm	11.8
43	25	NOVAMOXIN	Jan-79	Novopharm	-29.9	93	85	APO-IBUPROFEN	Nov-83	Apotex	4.2
44	41	APO-PREDNISONE	Mar-82	Apotex	2.7	94	94	APO-ACETAMINOPHEN	Oct-82	Apotex	6.8
45	49	APO-NAPROXEN	Aug-82	Apotex	10.5	95	76	ACCUPRIL	Mar-92	Pfizer	-2.7
46	44	MARVELON	Jul-93	Organon	-1.1	96	78	COMBIVENT	Jan-96	Boehringer Ingelheim	-1.3
47	53	APO-WARFARIN	Dec-00	Apotex	14.1	97	80	DIDROCAL	Nov-95	P&G Pharma	-1.9
48	50	NOVO-METOPROL	Mar-86	Novopharm	9.6	98	74	NOVO-METFORMIN	Apr-94	Novopharm	-9.3
49	54	FLOMAX	Jun-98	Biovail	12.8	99	485	APO-ALENDRONATE	Jun-04	Apotex	489
50	52	APO-ALLOPURINOL	Jun-81	Apotex	9.9	100	81	APO-SERTRALINE	Sep-99	Apotex	-2.2

\*Ranking based on the estimated number of prescriptions dispensed in Canadian retail pharmacies in the 12 months ending September 2006 and September 2005, respectively; \*\*% change from 12 months ending September 2005 to 12 months ending September 2006

Rank '06	Rank '05	Product	Launch Date (mmyy)	Manufacturer	% change**	Rank '06	Rank '05	Product	Launch Date (mmyy)	Manufacturer	% change**
101	114	ARICEPT	Aug-97	Pfizer	13.6	151	480	NOVO-BUPROPION SR	Mar-05	Novopharm	260.5
102	110	GEN-PAROXETINE	Oct-06	Genpharm	7.8	152	212	APO-CLONAZEPAM	Sep-95	Apotex	44.1
103	93	VIAGRA	Mar-99	Pfizer	-3.2	153	152	APO-DILTIAZ CD	Nov-96	Apotex	4.1
104	73	TRIPHASIL	Feb-83	Wyeth	-17.6	154	174	GEN-CLONAZEPAM	May-97	Genpharm	14.6
105	103	APO-DIAZEPAM	Jun-79	Apotex	-0.4	155	168	MACROBID	Jan-94	P&G Pharma	11.7
106	124	ENDOCET	Sep-87	Linson Pharma	20.2	156	177	HYDERM	Nov-79	Taro Pharma	16.2
107	109	APO-PEN-VK	Jan-86	Apotex	2.8	157	141	HUMULIN N	Jul-83	Lilly	-8.2
108	95	LIPIDIL SUPRA	May-00	Fourmier	-6.1	158	148	APO-PRAVASTATIN	Mar-01	Apotex	-4.8
109	84	TARO-WARFARIN	Oct-00	Taro Pharma	-11.5	159	151	NOVO-DIVALPROEX	Apr-99	Novopharm	0
110	117	PMS-ATENOLOL	Nov-98	Pharmascience	8.6	160	170	APO-TRAZODONE	May-95	Apotex	10.8
111	128	RATIO-METFORMIN	Jun-01	Ratiopharm	16.4	161	189	CONCERTA	Aug-03	Janssen-Ortho	25.1
112	108	APO-TRIAZIDE	Apr-84	Apotex	-2.4	162	140	TYLENOL W/COD #2	Jan-71	Janssen-Ortho	-11.1
113	130	APO-DIVALPROEX	May-99	Apotex	17.7	163	131	ADVANTAGE COMFORT	Jul-98	Riva	-19.1
114	119	FUCIDIN	Jan-80	Leo Pharma	6.2	164	159	DURAGESIC	May-92	Janssen-Ortho	2.5
115	100	GEN-RANITIDINE	Mar-96	Genpharm	-8.9	165	118	PMS-MELOXICAM	Nov-03	Pharmascience	-28.1
116	111	NOVO-ATENOL	Feb-91	Novopharm	-2.4	166	166	APO-TEMAZEPAM	Sep-96	Apotex	6
117	99	APO-ATENOL	Aug-88	Apotex	-9.9	167	197	ACTOS	Aug-00	Lilly	22.6
118	91	GEN-ZOPICLONE	Aug-98	Genpharm	-12.9	168	179	APO-ZOPICLONE	Nov-96	Apotex	9.3
119	129	NOVO-SPIROTON	Feb-84	Novopharm	13.5	169	183	APO-FERROUS GLUCONATE	Nov-81	Apotex	12.4
120	133	MICARDIS	Sep-99	Boehringer Ingelheim	16.9	170	165	NOVOLIN GE NPH	Aug-93	Novo Nordisk Canada	2.9
121	132	SYMBICORT	Feb-02	AstraZeneca	14	171	600	YASMIN	Dec-04	Berlex Canada	348.7
122	125	SINGULAIR	Aug-98	Merck Frosst	8.9	172	198	PROSCAR	Nov-92	Merck Frosst	20.5
123	169	ENZETROL	Jun-03	Merck-Schering GP	48.6	173	349	ASCENSIA MICROFILL	Oct-03	Bayer Pharma	128.4
124	105	RATIO-ATENOLOL	Mar-96	Ratiopharm	-11.8	174	185	NOVO-NAPROX	Sep-82	Novopharm	12.2
125	149	SPIRIVA	Jan-03	Boehringer Ingelheim	26	175	155	NOVO-PRAVASTATIN	Jan-03	Novopharm	-6.8
126	126	PMS-CLONAZEPAM	Jan-94	Pharmascience	6.1	176	143	CAL-500	Aug-86	Pro Doc	-15.6
127	104	APO-SALVENT CFC FREE	Nov-02	Apotex	-13.1	177	172	COSOPT	May-99	Merck Frosst	2.1
128	144	VALTREX	May-96	GlaxoSmithKline	20.5	178	120	CELEXA	Mar-99	Lundbeck Canada	-32.8
129	62	TIAZAC	May-97	Biovail	-39.3	179	190	LOPRESOR SR	Dec-82	Novartis	11.8
130	137	SENOKOT	Jan-56	Purdue Pharma	11.2	180	171	PROMETRIUM	Jun-95	Schering	-1.2
131	72	WELLBUTRIN SR	May-98	Biovail	-33.9	181	227	GEN-ATENOLOL	Jul-95	Genpharm	32.4
132	113	CEFZIL	Oct-95	Bristol-Myers Squibb	-11.5	182	224	TWINRIX	Sep-97	GlaxoSmithKline	29.7
133	127	NICODERM	Jun-92	Pfizer	-1.4	183	178	PMS-GABAPENTIN	Feb-01	Pharmascience	0.2
134	242	RATIO-LENOLTEC #3	Nov-85	Ratiopharm	95.2	184	175	NOVO-GABAPENTIN	Jul-02	Novopharm	-1.9
135	139	PMS-METOPROLOL-L	Oct-97	Pharmascience	9.4	185	202	ADVAIR MDI	Jan-02	GlaxoSmithKline	15.5
136	134	ELOCOM	Jan-91	Schering	2	186	192	EMO-CORT	Oct-62	Stiefel	8.9
137	42	ZITHROMAX	Sep-94	Pfizer	-57	187	167	RATIO-EMTEC	Apr-84	Ratiopharm	-5.7
138	671	NOVO-ALENDRONATE	May-03	Novopharm	560.1	188	206	AVELOX	Oct-00	Bayer Pharma	15.7
139	150	APO-CAL	Mar-86	Apotex	9.2	189	220	CIALIS	Nov-03	Lilly	24.3
140	146	SOFLAX	May-87	Pharmascience	7.1	190	180	LAMISIL	May-93	Novartis	-0.5
141	115	GEN-GLYBE	Jan-91	Genpharm	-16.4	191	182	ESTRACE	Apr-76	Shire Canada	0.2
142	147	IMOVANE	Aug-90	Sanofi-Aventis	5.4	192	156	PMS-FERROUS SULFATE	Feb-85	Pharmascience	-13.3
143	164	BIAXIN XL	Aug-02	Abbott	21.6	193	181	NOVO-QUININE	Jan-66	Novopharm	-0.4
144	136	RATIO-ECTOSONE	Feb-85	Ratiopharm	-3.7	194	248	DOCUSATE SODIUM	Dec-86	Taro Pharma	37.1
145	142	APO-SULFATRIM DS	Jan-79	Apotex	1.7	195	194	APO-METRONIDAZOLE	Jun-82	Apotex	6.9
146	154	BETADERM	Aug-79	Taro Pharma	10.7	196	161	RATIO-DILTIAZEM CD	Dec-96	Ratiopharm	-12.4
147	138	DIANE-35	Apr-98	Berlex Canada	-3.2	197	176	RATIO-MPA	Jul-96	Ratiopharm	-7.3
148	145	IMDUR	Oct-94	AstraZeneca	0.4	198	199	SERC	Jan-68	Solvay Pharma	6.6
149	135	EURO-D	Jan-01	Europharm	-9	199	204	APO-K	Jul-83	Apotex	7.2
150	454	APO-BISOPROLOL	Oct-04	Apotex	239.5	200	173	ZITHROMAX PEDIATRIC	Sep-96	Pfizer	-10.3

\*Ranking based on the estimated number of prescriptions dispensed in Canadian retail pharmacies in the 12 months ending September 2006 and September 2005, respectively; \*\*% change from 12 months ending September 2005 to 12 months ending September 2006

Rank '06	Product	Launch Date (mmyy)	Manufacturer	Estimated number of new Rxs (000's)	Rank '06	Product	Launch Date (mmyy)	Manufacturer	Estimated number of new Rxs (000's)
1	TYLENOL W/COD #3	Jan-71	Janssen-Ortho	3,538	51	APO-OXAZEPAM	Sep-79	Apotex	585
2	LIPITOR	Mar-97	Pfizer	3,351	52	TRI-CYCLEN	Jul-93	Janssen-Ortho	556
3	APO-AMOXI	Aug-84	Apotex	2,730	53	VASOTEC	Aug-87	Merck Frosst	547
4	ALTACE	Jan-94	Sanofi-Aventis	2,716	54	PLAVIX	Oct-98	BMS-Sanofi	541
5	SYNTHROID	Jan-57	Abbott	2,535	55	PMS-METFORMIN	Feb-97	Pharmascience	539
6	EFFEXOR XR	Mar-98	Wyeth	2,083	56	APO-SULFATRIM DS	Jan-79	Apotex	532
7	RATIO-SALBUTAMOL HFA	Feb-02	Ratiopharm	2,028	57	MACROBID	Jan-94	P&G Pharma	507
8	NORVASC	Sep-92	Pfizer	1,712	58	APO-OMEPRAZOLE	Jan-04	Apotex	493
9	NOVAMOIXIN	Jan-79	Novopharm	1,583	59	ELOCOM	Jan-91	Schering	490
10	FLOVENT HFA	Feb-02	GlaxoSmithKline	1,356	60	ACTONEL	Nov-99	P&G Pharma	477
11	APO-HYDRO	Oct-74	Apotex	1,290	61	HYDERM	Nov-79	Taro Pharma	477
12	APO-LORAZEPAM	Nov-85	Apotex	1,195	62	TYLENOL W/COD #2	Jan-71	Janssen-Ortho	471
13	PANTOLOC	Mar-97	Altana Pharma	1,172	63	APO-ALLOPURINOL	Jun-81	Apotex	466
14	APO-NAPROXEN	Aug-82	Apotex	1,153	64	BETADERM	Aug-79	Taro Pharma	461
15	APO-FUROSEMIDE	Jun-76	Apotex	1,060	65	AVELOX	Oct-00	Bayer Pharma	460
16	PARIET	Jul-02	Janssen-Ortho	1,047	66	APO-RANITIDINE	Mar-87	Apotex	459
17	APO-PREDNISONE	Mar-82	Apotex	1,037	67	DIOVAN	Nov-97	Novartis	452
18	RATIO-OXYCOCET	Apr-84	Ratiopharm	1,028	68	AVAPRO	Jun-98	BMS-Sanofi	449
19	NASONEX	Aug-98	Schering	1,021	69	RATIO-ECTOSONE	Feb-85	Ratiopharm	446
20	APO-CEPHALEX	Aug-88	Apotex	1,000	70	RATIO-EMTEC	Apr-84	Ratiopharm	439
21	ATIVAN	Apr-77	Wyeth	999	71	ZYPREXA	Nov-96	Lilly	438
22	NOVO-HYDRAZIDE	Jan-70	Novopharm	954	72	ZITHROMAX PEDIATRIC	Sep-96	Pfizer	437
23	CRESTOR	Feb-03	AstraZeneca	953	73	APO-METRONIDAZOLE	Jun-82	Apotex	437
24	APO-AMITRIPTYLINE	Jun-75	Apotex	952	74	APO-CITALOPRAM	Jan-04	Apotex	433
25	BIAXIN BID	Jul-92	Abbott	952	75	PMS-CLONAZEPAM-R	Mar-96	Pharmascience	424
26	CELEBREX	Apr-99	Pfizer	940	76	ATACAND	Dec-98	AstraZeneca	424
27	ASAPHEN	May-95	Pharmascience	902	77	MARVELON	Jul-93	Organon	417
28	APO-PEN-VK	Jan-86	Apotex	817	78	NOVO-LORAZEM	Apr-85	Novopharm	417
29	ALESSE	Jan-98	Wyeth	816	79	APO-SALVENT CFC FREE	Nov-02	Apotex	409
30	ADALAT XL	Apr-92	Bayer Pharma	803	80	APO-DIAZEPAM	Jun-79	Apotex	405
31	SEROQUEL	Jan-98	AstraZeneca	764	81	ADVAIR	Oct-99	GlaxoSmithKline	401
32	ELTROXIN	Jan-51	GlaxoSmithKline	764	82	DIDROCAL	Nov-95	P&G Pharma	397
33	ARTHROTEC	Apr-93	Pfizer	730	83	LANOXIN	Jan-36	Virco Pharma	397
34	APO-IBUPROFEN	Nov-83	Apotex	725	84	COVERSYL	Nov-94	Servier Lab	397
35	OXYCONTIN	Aug-96	Purdue Pharma	704	85	CIPRO XL	Aug-03	Bayer Pharma	392
36	FUCIDIN	Jan-80	Leo Pharma	694	86	NOVO-METOPROL	Mar-86	Novopharm	391
37	NOVASEN	Jan-76	Novopharm	688	87	NOVO-LEXIN	Feb-80	Novopharm	389
38	ENDOCET	Sep-87	Linson Pharma	683	88	NITRO-DUR	Feb-91	Schering	386
39	PREMARIN	Feb-42	Wyeth	675	89	VALTRES	May-96	GlaxoSmithKline	384
40	CEFZIL	Oct-95	Bristol-Myers Squibb	671	90	APO-AZITHROMYCIN	Nov-05	Apotex	383
41	NEXIUM	Aug-01	AstraZeneca	648	91	APO-METOPROLOL	Oct-84	Apotex	377
42	FLOXAN	Sep-93	GlaxoSmithKline	646	92	GEN-ZOPICLONE	Aug-98	Genpharm	375
43	ZITHROMAX	Sep-94	Pfizer	645	93	DURAGESIC	May-92	Janssen-Ortho	374
44	LOSEC	Jun-89	AstraZeneca	640	94	NOVO-NAPROX	Sep-82	Novopharm	374
45	APO-WARFARIN	Dec-00	Apotex	627	95	APO-ACETAMINOPHEN	Oct-82	Apotex	373
46	RISPERDAL	May-93	Janssen-Ortho	620	96	APO-AMOXI CLAV	Jun-01	Apotex	370
47	BIAXIN XL	Aug-02	Abbott	610	97	COUMADIN	May-56	Bristol-Myers Squibb	368
48	PREVACID	Jun-95	Abbott	607	98	FLOMAX	Jun-98	Boehringer Ingelheim	367
49	RATIO-LENOLTEC #3	Nov-85	Ratiopharm	601	99	BIAXIN PEDIATRIC	Mar-95	Abbott	365
50	GEN-METFORMIN	Apr-95	Genpharm	589	100	DILAUDID	Mar-70	Abbott	363

\*Ranking based on the estimated number of prescriptions dispensed in Canadian retail pharmacies in the 12 months ending September 2006.

Rank '06	Product	Launch Date (mmyy)	Manufacturer	Estimated number of refill Rxs (000's)	Rank '06	Product	Launch Date (mmyy)	Manufacturer	Estimated number of refill Rxs (000's)
1	LIPITOR	Mar-97	Pfizer	8,956	51	CARBOCAL D 400	Jul-02	Europharm	894
2	SYNTHROID	Jan-57	Abbott	7,063	52	APO-SIMVASTATIN	Jan-03	Apotex	884
3	ALTACE	Jan-94	Sanofi-Aventis	6,036	53	SANDOZ-BISOPROLOL	Aug-03	Sandoz	868
4	ASAPHEN	May-95	Pharmascience	4,568	54	APO-WARFARIN	Dec-00	Apotex	858
5	NORVASC	Sep-92	Pfizer	4,387	55	NITRO-DUR	Feb-91	Schering	846
6	EFFEXOR XR	Mar-98	Wyeth	3,484	56	COZAAR	Oct-95	Merck Frosst	843
7	PANTOLOC	Mar-97	Altana Pharma	3,147	57	NOVO-SEMIDE	Aug-76	Novopharm	819
8	APO-FUROSEMIDE	Jun-76	Apotex	2,660	58	AVANDIA	Mar-00	GlaxoSmithKline	812
9	NOVASEN	Jan-76	Novopharm	2,328	59	NOVO-GLYBURIDE	Nov-91	Novopharm	789
10	APO-HYDRO	Oct-74	Apotex	2,269	60	COVERSYL	Nov-94	Servier Lab	788
11	CRESTOR	Feb-03	AstraZeneca	2,023	61	APO-CITALOPRAM	Jan-04	Apotex	785
12	NOVO-HYDRAZIDE	Jan-70	Novopharm	1,945	62	APO-METOPROLOL	Oct-84	Apotex	764
13	SEROQUEL	Jan-98	AstraZeneca	1,930	63	DILANTIN SODIUM	Jan-52	Pfizer	744
14	ADALAT XL	Apr-92	Bayer	1,913	64	PMS-CLONAZEPAM-R	Mar-96	Pharmascience	742
15	ALESSE	Jan-98	Wyeth	1,889	65	AVALIDE	Apr-00	BMS-Sanofi	733
16	PARIET	Jul-02	Janssen-Ortho	1,888	66	APO-METOPROLOL-L	May-87	Apotex	723
17	RISPERDAL	May-93	Janssen-Ortho	1,837	67	ARICEPT	Aug-97	Pfizer	722
18	PLAVIX	Oct-98	BMS-Sanofi	1,831	68	APO-FOLIC	Jun-78	Apotex	720
19	RATIO-SALBUTAMOL HFA	Feb-02	Ratiopharm	1,771	69	NOVO-METFORMIN	Apr-94	Novopharm	718
20	PREMARIN	Feb-42	Wyeth	1,693	70	APO-METFORMIN	Sep-95	Apotex	713
21	ACTONEL	Nov-99	P&G Pharma	1,646	71	APO-RANITIDINE	Mar-87	Apotex	709
22	NEXIUM	Aug-01	AstraZeneca	1,517	72	ASPIRIN	Jan-51	Bayer Pharma	697
23	ATIVAN	Apr-77	Wyeth	1,494	73	GEN-SIMVASTATIN	Feb-03	Genpharm	686
24	APO-AMITRIPTYLINE	Jun-75	Apotex	1,452	74	ONE TOUCH ULTRA	Mar-01	Lifescan	682
25	APO-LORAZEPAM	Nov-85	Apotex	1,397	75	ADVAIR	Oct-99	GlaxoSmithKline	682
26	ELTROXIN	Jan-51	GlaxoSmithKline	1,382	76	DIOVAN HCT	May-00	Novartis	679
27	ZYPREXA	Nov-96	Lilly	1,357	77	APO-LISINAPRIL	Dec-96	Apotex	678
28	APO-OXAZEPAM	Sep-79	Apotex	1,346	78	NOVO-GESIC	Nov-82	Novopharm	670
29	TRI-CYCLEN	Jul-93	Janssen-Ortho	1,345	79	ACCUPRIL	Mar-92	Pfizer	669
30	VASOTEC	Aug-87	Merck Frosst	1,305	80	APO-PAROXETINE	Oct-03	Apotex	664
31	LANOXIN	Jan-36	Virco Pharma	1,305	81	APO-GLYBURIDE	Nov-91	Apotex	660
32	LOSEC	Jun-89	AstraZeneca	1,291	82	APO-ALENDRONATE	Jun-04	Apotex	656
33	PREVACID	Jun-95	Abbott	1,263	83	GEN-CITALOPRAM	Feb-04	Genpharm	650
34	APO-OMEPRAZOLE	Jan-04	Apotex	1,226	84	LIPIDIL SUPRA	May-00	Fournier	631
35	GEN-METFORMIN	Apr-95	Genpharm	1,221	85	TRIPHASIL	Feb-83	Wyeth	629
36	CELEBREX	Apr-99	Pfizer	1,211	86	NASONEX	Aug-98	Schering	624
37	AVAPRO	Jun-98	BMS-Sanofi	1,189	87	COMBIVENT	Jan-96	Boehringer Ingelheim	594
38	PMS-METFORMIN	Feb-97	Pharmascience	1,154	88	APO-DIVALPROEX	May-99	Apotex	590
39	RIVASA	Mar-00	Riva	1,139	89	APO-SERTRALINE	Sep-99	Apotex	585
40	FLOVENT HFA	Feb-02	GlaxoSmithKline	1,119	90	APO-ACETAMINOPHEN	Oct-82	Apotex	573
41	NOVO-METOPROL	Mar-86	Novopharm	1,091	91	APO-PREDNISONE	Mar-82	Apotex	569
42	FLOMAX	Jun-98	Boehringer Ingelheim	1,084	92	VIAGRA	Mar-99	Pfizer	565
43	MARVELON	Jul-93	Organon	1,074	93	NOVO-ATENOL	Feb-91	Novopharm	559
44	COUMADIN	May-56	Bristol-Myers Squibb	1,046	94	FLONASE	Sep-93	GlaxoSmithKline	559
45	FOSAMAX	Jan-96	Merck Frosst	1,037	95	PMS-ATENOLOL	Nov-98	Pharmascience	559
46	ATACAND	Dec-98	AstraZeneca	973	96	NOVO-LORAZEM	Apr-85	Novopharm	554
47	APO-ALLOPURINOL	Jun-81	Apotex	973	97	TYLENOL W/COD #3	Jan-71	Janssen-Ortho	549
48	CALCITE 500+D 400	Oct-02	Riva	971	98	RATIO-METFORMIN	Jun-01	Ratiopharm	545
49	DIOVAN	Nov-97	Novartis	959	99	GEN-PAROXETINE	Oct-03	Genpharm	544
50	XALATAN	Jul-97	Pfizer	947	100	NOVO-SPIROTON	Feb-84	Novopharm	544

\*Ranking based on the estimated number of prescriptions dispensed in Canadian retail pharmacies in the 12 months ending September 2006.